Private equity deals with life sciences organizations rely on technical details that generalist firms miss. Alkemi gives you the specialized intelligence to confirm or challenge assumptions before you commit capital.
.avif)
.avif)
Private equity firms are experts in capital and deal mechanics. But in life sciences, investment models hinge on technical details like whether a therapy will be reimbursed in major markets, how prescribing volumes are likely to trend, where evidence is lacking for adoption, and what HTA outcomes and pricing trends mean for revenue forecasts.
Without strong data integration across these inputs, even small blind spots can distort valuations. That’s where Alkemi comes in. We help investors identify and overcome blind spots with...
Technical due diligence that validates or challenges your investment thesis
Granular market access intelligence that generalist firms miss
Portfolio company value-add that strengthens adoption strategies and accelerates returns
Alkemi gives investors technical clarity by turning scattered data and analytics into predictive insights that guide investment decisions. We also partner with Private Equity portfolio companies to strengthen market access strategy, align business goals, and accelerate growth in global markets.
Whether your portfolio company is:
A biotech seeking payer approval and health technology assessment (HTA) validation
A pharma company navigating reimbursement processes and price negotiations
Or a life sciences player designing their pivotal clinical trial and payer value proposition
For assets still in development, Launch Shield™ builds early visibility into reimbursement pathways and regulatory requirements. The result: portfolio companies launch faster, with payer-ready strategies that hold up in front of decision makers.
Starting at
$150k
When a portfolio company faces payer pushback or stalled reimbursement, speed is everything. Our Access Threat Response System™ delivers a realigned access plan in 90 days or less — protecting commercial potential and investor confidence.
Starting at
$100k
We live and breathe market access and HEOR every day, so we deliver the detailed answers investors need with speed and urgency.
Our ability to cover the UK, France, Germany, Spain, and Italy (in local language, with HTA expertise) gives you global visibility competitors lack. That’s why we’re chosen over larger firms when investors need due diligence in Europe.
We translate complex data into clear, actionable insights that include market headwinds/tailwinds, tariff policies, pricing outlook, and reimbursement risks to directly inform your investment decisions.
Beyond diligence, we help MedTech and biotech assets align on best practices, sharpen their value propositions, and execute access strategies that accelerate adoption, increase revenues and investor returns.
Private equity firms turn to Alkemi when diligence questions get too technical for internal teams, and too urgent for broad-market consultants.
Our work has validated investment theses before capital was deployed, uncovered hidden reimbursement risks that could have undermined valuations, and accelerated portfolio company access strategies under tight timelines.
We’ve helped life science companies launch 50+ treatments, delivered access strategies in as little as 90 days, and provided global perspective through EU4 + UK capabilities.
Our expertise spans diagnostics, oncology, immunology, rare disease, obesity, and advanced cell and gene therapies.
Investors rely on us for the kind of decision-ready intelligence that protects deal value and propels portfolio growth.
"Thanks again for pulling together a great team, appreciate it a lot. Hope this is one of many engagements with us, will flag you and Alkemi to our US Healthcare Team as well."
"Really appreciate your support - as you know I rang you in a bit of a panic a few weeks ago, yet the session came across as though you’d been working on it for months. Thank you so much - this is an important event for our team, companies and clients - and you really helped make it a success. I heard 3 groups leave with ambitions to up their game - and they’re the 3 that need to do it the most - so the message landed as well."
"When I presented the project output to our leadership, they said: 'You took a really scary situation and broke it down in terms we understand. It sounds like the team has a clear plan going forward'. That was my goal for this project so sounds like we achieved it."
![image of successful businesses [headshot]](https://cdn.prod.website-files.com/68c86636bce64aae0bd583b2/68c86c59ad68004ea9ddd6b4_c1cd2a51-1f06-45cb-9a13-4199a77f0015.avif)
“They helped us identify our evidence gaps and develop a solid communication tool aligned with stakeholder needs. And they’re fun to work with!”
![[headshot]](https://cdn.prod.website-files.com/68c86636bce64aae0bd583b2/68c86c59dcf34a6442165770_122204b6-f407-479f-9bb7-84c323ad8f65.avif)
"Thanks again for pulling together a great team, appreciate it a lot. Hope this is one of many engagements with Warburg, will flag you and Alkemi to our US Healthcare Team as well."
![[headshot] image of customer (for a home inspector)](https://cdn.prod.website-files.com/68c86636bce64aae0bd583b2/68c86c5aee875a9e30534dab_da918c69-68ea-42eb-8ad0-fd4f176193a5.avif)
Our business intelligence solutions are built for the unique demands of Private Equity companies. Alkemi delivers insights and actionable recommendations validated by on the ground decision makers enabling you to move faster with confidence.
We stress-test your assumptions with market access and HEOR data — from prescribing volume forecasts to reimbursement likelihood — so you know whether the numbers behind a deal actually hold up.
When diligence questions turn technical, we provide clear answers on reimbursement pathways, regulatory hurdles, and competitive dynamics that can change the value of an asset overnight.
Our on-the-ground teams in France, Germany, Spain, Italy, and the UK bring local language expertise and HTA insight, giving you visibility across the markets that drive global revenue.
After the deal closes, we work directly with portfolio companies to refine market access strategies, align stakeholders, and remove barriers that slow adoption. So you can turn diligence insights into portfolio value.
When you need a quick read from external decisionmakers Alkemi has a global network of payer, providers and policy makers to get your questions answered fast.
Schedule a Strategy Call with Alkemi and get the data, insights, and strategies private equity firms need to move quickly, reduce risk, and grow portfolio value.
“Access strategies executed in 90 days instead of 6-12 months, enabling us to act within the critical 30-day decision window, when access positions were still in flux and competitors were unprepared.”
“I wanted to reach out and tell you that the publication is getting GREAT reception from senior BU leadership across the company. Thank you again for your and Alkemi’s support on this project!”
“Stakeholder-validated access arguments built in 42 days, helping us retain Tier 2 formulary status and neutralize a competitor’s evidence positioning before revenue was impacted.”
“Payer value models and communication tools delivered in 45 days, giving our team immediate readiness for coverage discussions, cutting months from pricing and reimbursement timelines.”
"Really appreciate your support - as you know I rang you in a bit of a panic a few weeks ago, yet the session came across as though you’d been working on it for months. Thank you so much - this is an important event for our team, companies and clients - and you really helped make it a success. I heard 3 groups leave with ambitions to up their game - and they’re the 3 that need to do it the most - so the message landed as well."
“Patient access achieved 6 days post-approval, driving a 140% revenue increase and 90% share-price growth within 12 months through a precision-aligned market access plan.”
“Coverage positions worth $100M+ preserved after policy risks were contained and access arguments re-framed within 45 days of the initial threat.”
"When I presented the project output to our leadership, they said: 'You took a really scary situation and broke it down in terms we understand. It sounds like the team has a clear plan going forward'.
“Launch readiness across 7 key markets accelerated by 6 months, improving payer perception, price confidence, and HTA alignment for sustained commercial success.”
“Cross-functional alignment reached in 21 days, uniting medical, HEOR, and commercial stakeholders around payer-critical priorities and evidence generation plans.”
“Research engagement delivered 5X more patients and 6X more clinicians than prior studies, compressing evidence-collection timelines by over 12 months.”
"Thanks to the whole team involved in staging this Advisory Council. I was fortunate to be able to attend and here the insights from the council members firsthand. The report provides an excellent summary."
“Guideline and compendia updates secured within 7 days of approval, converting scientific validation into immediate payer endorsement and market adoption.”